Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer

NCT06959082 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Cancer Squamous Cell Carcinoma

Interventions

DRUG: VS-101
DRUG: Cisplatin
RADIATION: Radiation

Sponsor

VSPharmTech Co.,Ltd.